YU25500A - Postupak za sintezu analoga nukleozida - Google Patents

Postupak za sintezu analoga nukleozida

Info

Publication number
YU25500A
YU25500A YU25500A YUP25500A YU25500A YU 25500 A YU25500 A YU 25500A YU 25500 A YU25500 A YU 25500A YU P25500 A YUP25500 A YU P25500A YU 25500 A YU25500 A YU 25500A
Authority
YU
Yugoslavia
Prior art keywords
nucleosite
synthesis
analogues
protected
heterocycluse
Prior art date
Application number
YU25500A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
Robert William Scott
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of YU25500A publication Critical patent/YU25500A/sh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14Pyrrolo-pyrimidine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
YU25500A 1999-05-11 2000-05-03 Postupak za sintezu analoga nukleozida YU25500A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13365199P 1999-05-11 1999-05-11

Publications (1)

Publication Number Publication Date
YU25500A true YU25500A (sh) 2003-08-29

Family

ID=22459680

Family Applications (1)

Application Number Title Priority Date Filing Date
YU25500A YU25500A (sh) 1999-05-11 2000-05-03 Postupak za sintezu analoga nukleozida

Country Status (22)

Country Link
US (1) US6271370B1 (cg-RX-API-DMAC7.html)
EP (1) EP1052264B1 (cg-RX-API-DMAC7.html)
JP (1) JP2001011092A (cg-RX-API-DMAC7.html)
KR (1) KR100403900B1 (cg-RX-API-DMAC7.html)
CN (1) CN1275575A (cg-RX-API-DMAC7.html)
AR (1) AR028991A1 (cg-RX-API-DMAC7.html)
AT (1) ATE291582T1 (cg-RX-API-DMAC7.html)
AU (1) AU3401100A (cg-RX-API-DMAC7.html)
BR (1) BR0002089A (cg-RX-API-DMAC7.html)
CA (1) CA2307951A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20001710A3 (cg-RX-API-DMAC7.html)
DE (1) DE60018833D1 (cg-RX-API-DMAC7.html)
HU (1) HUP0001843A3 (cg-RX-API-DMAC7.html)
ID (1) ID25992A (cg-RX-API-DMAC7.html)
IL (1) IL136027A0 (cg-RX-API-DMAC7.html)
IN (1) IN186850B (cg-RX-API-DMAC7.html)
MX (1) MXPA00004532A (cg-RX-API-DMAC7.html)
PL (1) PL340109A1 (cg-RX-API-DMAC7.html)
RU (1) RU2200738C2 (cg-RX-API-DMAC7.html)
TR (1) TR200001340A2 (cg-RX-API-DMAC7.html)
YU (1) YU25500A (cg-RX-API-DMAC7.html)
ZA (1) ZA200002263B (cg-RX-API-DMAC7.html)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
CA2574651C (en) * 2004-07-21 2013-05-21 Pharmasset, Inc. Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
JP5138585B2 (ja) 2005-05-05 2013-02-06 アーディア・バイオサイエンシーズ・インコーポレイテッド Hivの処置のための非ヌクレオシド逆転写酵素インヒビターとしてのジアリル−プリン、−アザプリンおよび−デアザプリン
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
NZ566068A (en) 2005-08-08 2011-03-31 Argenta Discovery Ltd Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
EP1957530A2 (en) 2005-10-21 2008-08-20 Novartis AG Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
MX2009003185A (es) 2006-09-29 2009-04-03 Novartis Ag Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
BRPI0718266A2 (pt) 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
CA2709176C (en) 2007-12-14 2013-02-05 Ardea Biosciences, Inc. Reverse transcriptase inhibitors
EA017573B1 (ru) 2007-12-14 2013-01-30 Пульмаджен Терапьютикс (Эсме) Лимитед Производные индол-1-илуксусной кислоты и их терапевтическое применение
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
CN102395586A (zh) 2009-02-17 2012-03-28 奇斯药制品公司 作为p38map激酶抑制剂的三唑并吡啶衍生物
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions
WO2011005860A2 (en) * 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EP2464649A1 (en) 2009-08-12 2012-06-20 Novartis AG Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
ES2709108T3 (es) 2009-08-17 2019-04-15 Intellikine Llc Compuestos heterocíclicos y usos de los mismos
BR112012008061A2 (pt) 2009-08-20 2016-03-01 Novartis Ag compostos de oxima heterocíclica
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
AU2012220572A1 (en) 2011-02-25 2013-08-29 Irm Llc Compounds and compositions as trk inhibitors
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
CN104363914A (zh) 2011-11-23 2015-02-18 因特利凯有限责任公司 使用mTOR抑制剂的增强的治疗方案
BR112014013178A2 (pt) 2011-12-09 2017-06-13 Chiesi Farm Spa composto, composição farmacêutica e uso de um composto
AU2012347350C1 (en) 2011-12-09 2017-01-19 Chiesi Farmaceutici S.P.A. Kinase inhibitors
JP6145849B2 (ja) 2011-12-09 2017-06-14 チエシ ファルマスーティシ エス.ピー.エー. キナーゼ阻害剤
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
BR112014032913A2 (pt) 2012-06-29 2017-06-27 Pfizer novas 4-(amino-substituídas)-7h-pirrolo[2,3-d]pirimidinas como inibidores de lrrk2
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
WO2014195402A1 (en) 2013-06-06 2014-12-11 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CA2922770A1 (en) 2013-09-05 2015-03-12 F. Hoffmann-La Roche Ag Triazolopyridine compounds, compositions and methods of use thereof
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Mdm2抑制劑與BRAF抑制劑之組合及其用途
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク LRRK2阻害薬としての新規の3,4−二置換−1H−ピロロ[2,3−b]ピリジンおよび4,5−二置換−7H−ピロロ[2,3−c]ピリダジン
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
WO2016016822A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
JP2018507236A (ja) 2015-03-04 2018-03-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft トリアゾロピリジン化合物及びその使用法
AU2016322813B2 (en) 2015-09-14 2021-04-01 Pfizer Inc. Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
AR107163A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa Inhibidores de quinasa
MA44131A (fr) 2015-12-23 2021-05-26 Chiesi Farm Spa Dérivés de 1-(3-tert-butyl-2h-pyrazol-5-yl or 5-tert-butyl-isoxaol-3-yl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalenyl) urée et leur utlisation en tant qu'inhibiteurs de p38 mapk
TW201730189A (zh) 2015-12-23 2017-09-01 吉斯藥品公司 激酶抑制劑
EP3452464B1 (en) 2016-05-05 2021-12-15 F. Hoffmann-La Roche AG Pyrazole derivatives, compositions and therapeutic use thereof
AU2017324281A1 (en) 2016-09-06 2019-03-21 F. Hoffmann-La Roche Ag 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-A]pyridinyl compounds, compositions and methods of use thereof
CR20190310A (es) 2016-12-29 2019-08-21 Hoffmann La Roche Compuestos de pirazolopirimidina y métodos de uso de los mismos
WO2018166993A2 (en) 2017-03-14 2018-09-20 F. Hoffmann-La Roche Ag Pyrazolochlorophenyl compounds, compositions and methods of use thereof
JP7228318B6 (ja) 2017-05-22 2023-03-10 エフ. ホフマン-ラ ロシュ アーゲー 処置用化合物及び組成物、並びにその使用方法
RU2769696C2 (ru) 2017-05-22 2022-04-05 Ф. Хоффманн-Ля Рош Аг Терапевтические соединения и композиции и способы их применения
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
WO2019139714A1 (en) 2018-01-15 2019-07-18 Genentech, Inc. Pyrazolopyrimidine compounds as jak inhibitors
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
EP3986899A1 (en) 2019-06-18 2022-04-27 F. Hoffmann-La Roche AG Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof
KR20220024405A (ko) 2019-06-18 2022-03-03 에프. 호프만-라 로슈 아게 Jak 키나제의 피라졸로피리미딘 설폰 억제제 및 그 사용
WO2020257142A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
CN117343119A (zh) * 2022-06-29 2024-01-05 上海交通大学 一种烷基化核苷、核苷酸、寡核苷酸及其类似物的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61207400A (ja) * 1985-03-11 1986-09-13 Nippon Zoki Pharmaceut Co Ltd ヌクレオシド化合物の製造方法
US4751292A (en) 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US4859677A (en) 1987-04-17 1989-08-22 University Of Kansas Nucleoside analogues having antiviral activity
US5246931A (en) 1988-10-25 1993-09-21 Bristol-Myers Squibb Company Carbocyclic nucleoside analogs
US5688778A (en) 1989-05-15 1997-11-18 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleoside analogs
GB8916480D0 (en) 1989-07-19 1989-09-06 Glaxo Group Ltd Chemical process
US5726302A (en) * 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5276151A (en) 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5470857A (en) 1990-09-14 1995-11-28 Marion Merrell Dow Inc. Carbocyclic nucleoside analogs useful as immunosuppressants
SE9003151D0 (sv) 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
TW374087B (en) 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
AU3086495A (en) * 1994-08-02 1996-03-04 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazoles
US5659023A (en) 1995-02-01 1997-08-19 Gilead Sciences, Inc. Nucleotide analogues
WO1997027204A1 (en) 1996-01-23 1997-07-31 The Regents Of The University Of Michigan Modified benzimidazole nucleosides as antiviral agents

Also Published As

Publication number Publication date
AU3401100A (en) 2000-11-16
ATE291582T1 (de) 2005-04-15
HUP0001843A2 (hu) 2001-06-28
PL340109A1 (en) 2000-11-20
EP1052264A2 (en) 2000-11-15
KR20010069193A (ko) 2001-07-23
KR100403900B1 (ko) 2003-11-01
IL136027A0 (en) 2001-05-20
MXPA00004532A (es) 2002-03-08
US6271370B1 (en) 2001-08-07
TR200001340A2 (tr) 2000-12-21
EP1052264A3 (en) 2001-06-13
HU0001843D0 (en) 2000-07-28
ID25992A (id) 2000-11-16
BR0002089A (pt) 2001-01-02
RU2200738C2 (ru) 2003-03-20
AR028991A1 (es) 2003-06-04
EP1052264B1 (en) 2005-03-23
ZA200002263B (en) 2001-12-24
HUP0001843A3 (en) 2001-09-28
CN1275575A (zh) 2000-12-06
CZ20001710A3 (cs) 2001-09-12
IN186850B (cg-RX-API-DMAC7.html) 2001-11-24
JP2001011092A (ja) 2001-01-16
DE60018833D1 (de) 2005-04-28
CA2307951A1 (en) 2000-11-11

Similar Documents

Publication Publication Date Title
YU25500A (sh) Postupak za sintezu analoga nukleozida
HUP0200297A2 (en) Method for acylating peptides and the glutaminic acid derivatives as acylating agents
WO2003077867A3 (en) Naltrexone hydrochloride compositions
IL128829A0 (en) Improved solid-phase peptide and agent for use in such synthesis
TW437388U (en) Structure of universal, horizontal, electrical transportation vehicle
AU2001245928A1 (en) Electrolyzer and method of using the same
TWI256891B (en) 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
MY122278A (en) 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
IL150225A0 (en) Lipopeptides, pharmaceutical compositions containing the same and methods for the production thereof
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
BG103914A (en) Maintained separation of delayed gels
IL148803A0 (en) Novel composition and method for stabilizing the same
PL341549A1 (en) Novel-beta-carbolinic compounds, method of obtaining them and pharmacological compositions containing such compounds
GB9929552D0 (en) Compounds
WO2001040177A3 (en) Esters of vitamin d3 and uses thereof
AU5956001A (en) Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
ATE305771T1 (de) Verfahren zur herstellung von vitaminpulvern
GB2397059B (en) Method to improve the stability of dispersions of carbon
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
GR1004672B (el) Προτυπα αναφορας για τον προσδιορισμο της καθαροτητας ή σταθεροτητας της μιλεινικης αμλοδιπινης και διεργασιες για αυτα.
AU2003209560A1 (en) System and method for the reception of content items
AU2002349522A1 (en) Composition for electrolytic solution and process for producing the same
PL347179A1 (en) Tricyclic &dgr;3-piperidines as pharmaceuticals
AU2003283055A8 (en) Opioid-receptor antagonists in transdermal systems having buprenorphine
AU4306701A (en) Methods for producing gas microbubbles having lipid-containing shells formed thereon